Use of the Invertebrate Galleria mellonella as an Infection Model to Study the Mycobacterium tuberculosis Complex
June 30th, 2019
11.2K views
Galleria mellonella was recently established as a reproducible, cheap, and ethically acceptable infection model for the Mycobacterium tuberculosis complex. Here we describe and demonstrate the steps taken to establish successful infection of G. mellonella with bioluminescent Mycobacterium bovis BCG lux.
Overview
This protocol describes the use of Galleria mellonella as an alternative infection model to study tuberculosis, reducing the number of mammalian models used in research. Galleria mellonella is a cheaper, ethically acceptable, and more accessible model to study tuberculosis.
Key Study Components
Area of Science
- Infection models
- Mycobacterium tuberculosis research
- Ethical alternatives in research
Background
- Galleria mellonella has a complex innate immune system comparable to mammals.
- It has been widely used for other bacterial and fungal pathogens.
- This model allows for the study of host-pathogen interactions.
- Further optimization can aid in drug efficacy and toxicity screening.
Purpose of Study
- To establish Galleria mellonella as a model for tuberculosis research.
- To reduce reliance on traditional mammalian models.
- To contribute to the development of novel therapeutics for tuberculosis.
Methods Used
- Establishment of infection protocols for Galleria mellonella.
- Use of bioluminescent Mycobacterium bovis BCG lux.
- Comparative analysis with conventional mammalian models.
- Screening for candidate antimycobacterial drugs.
Main Results
- Successful infection of Galleria mellonella with Mycobacterium bovis BCG lux.
- Demonstrated potential for drug efficacy screening.
- Highlighted the ethical advantages of using Galleria mellonella.
- Revealed insights into innate immunity's role in tuberculosis.
Conclusions
- Galleria mellonella is a viable alternative for tuberculosis research.
- Further studies can enhance its application in drug development.
- This model can lead to a reduction in mammalian testing.
Frequently Asked Questions
What is Galleria mellonella?
Galleria mellonella, also known as the greater wax moth, is used as a model organism in infection studies.
Why use Galleria mellonella for tuberculosis research?
It offers a cost-effective and ethical alternative to traditional mammalian models.
How does Galleria mellonella's immune system compare to mammals?
It possesses a complex innate immune system that is comparable to that of mammals.
What are the advantages of using this model?
It reduces the number of mammals used in research and allows for efficient screening of drug candidates.
Can Galleria mellonella be used for other pathogens?
Yes, it has been widely used for various bacterial and fungal pathogens.
Executive Industry Relevance
High-throughput, ethically acceptable infection models are critical for accelerating tuberculosis drug discovery and reducing reliance on mammalian systems. The Galleria mellonella model enables rapid, quantitative assessment of mycobacterial virulence and drug efficacy, supporting early-stage portfolio triage. This approach addresses cost, scalability, and ethical constraints at the preclinical inflection point for anti-tuberculosis R&D.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of mycobacterial virulence and host-pathogen interactions in a living system.
- Supports biological de-risking by providing dose-dependent infection readouts.
- Facilitates functional validation of candidate targets prior to mammalian studies.
- Improves predictive confidence for advancing compounds into higher-cost models.
Screening & Assay Development
- Provides a reproducible, scalable platform for pre-screening drug efficacy and toxicity.
- Delivers quantitative bioluminescence and CFU outputs for standardized assay development.
- Enables rapid, high-throughput evaluation of compound libraries against mycobacteria.
- Reduces variability and resource requirements compared to mammalian models.
Translational & Preclinical Research
- Aligns with translational biomarker strategies by enabling in vivo infection monitoring.
- Supports continuity from early discovery through preclinical validation with measurable endpoints.
- De-risks progression by identifying ineffective or toxic compounds before mammalian testing.
- Facilitates comparative virulence studies across mycobacterial strains.
Pipeline & Workflow Integration
The Galleria mellonella infection model fits between in vitro screening and mammalian preclinical studies, enabling efficient triage and mechanistic de-risking.
- Discovery Biology: Supports hypothesis testing of mycobacterial pathogenicity and host response.
- Screening: Provides assay-ready, quantitative outputs for compound efficacy and toxicity.
- Analytics: Enables bioluminescence and CFU measurements for robust statistical comparison.
- Translational Research: Offers in vivo infection dynamics relevant to preclinical decision-making.
- Enterprise Reuse: Establishes a reusable, scalable infection platform for diverse anti-infective programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in early-stage TB research.
- Operational Value: Delivers standardized, reproducible, and scalable infection assays.
- Strategic Value: Enables better go/no-go decisions and capital efficiency by filtering candidates before mammalian studies.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of anti-tuberculosis assets.
Implementation Considerations
- Requires expertise in invertebrate handling and infection protocols.
- Needs access to bioluminescence measurement and CFU enumeration infrastructure.
- Demands cross-team standardization for reproducibility and data comparability.
- Adaptation may be needed for different mycobacterial strains or drug classes.
- Limited by incomplete genomic annotation for advanced transcriptomic analyses.
Biopharma FAQs
Why does null hypothesis testing matter for Galleria mellonella infection studies?
Null hypothesis testing enables objective assessment of mycobacterial virulence and drug efficacy by comparing survival and bioluminescence outputs between treated and control larvae. This statistical rigor supports target validation and mechanistic de-risking before advancing candidates. Reliable hypothesis testing reduces false positives and informs portfolio decisions.
How does independent variable isolation fit the Galleria mellonella infection workflow?
Isolating variables such as mycobacterial dose or compound concentration allows precise attribution of observed effects on larval survival and infection burden. This clarity is essential for dissecting mechanism of action and optimizing assay conditions in early discovery pipelines. Controlled variable manipulation underpins reproducible, interpretable results.
What do quantitative bioluminescence and CFU measurements enable in this model?
Quantitative bioluminescence and CFU outputs provide rapid, reproducible readouts of in vivo mycobacterial burden and infection dynamics. These measurements enable high-throughput screening, dose-response analysis, and comparative virulence assessment, supporting data-driven advancement decisions. They also facilitate cross-study and cross-team data integration.
Why are replication requirements critical for cross-functional tuberculosis research?
Replication ensures that infection and drug efficacy results are robust and reproducible across different operators, batches, and laboratories. This reliability is vital for cross-functional collaboration, enabling confidence in data used for portfolio triage and regulatory submissions. Standardized replication protocols reduce operational risk and support enterprise-wide adoption.
What statistical analysis capabilities are required before implementing Galleria mellonella infection assays?
Implementation requires statistical tools for survival analysis, such as the Mantel-Cox test, and for comparing bioluminescence and CFU data across groups. These analyses support rigorous interpretation of infection outcomes and drug effects, ensuring that only candidates with statistically significant benefits advance. Robust analytics underpin decision-making and portfolio management.
